Physician profile
Emily Sabbagh
NPI 1154400596
$10,005.05
in general payments reported to CMS, 2019-2025
33 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 91% of Oral and Maxillofacial Surgery providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $578 · 2021: $2,275 · 2022: $775 · 2023: $1,087 · 2024: $1,144 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,158.61 | 2019-2024 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $1,131.37 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $953.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $852.98 | 2019-2025 | Jardiance, Kisunla |
| Glaxosmithkline, LLC. | $742.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $587.80 | 2019-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $524.71 | 2021 | |
| Abbvie INC. | $351.41 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Corcept Therapeutics | $350.97 | 2025 | Korlym |
| Dexcom, INC. | $303.37 | 2024 | Dexcom G6 Transmitter |
| Galderma Laboratories, L.P. | $281.44 | 2019-2025 | Dysport |
| Bayer Healthcare Pharmaceuticals INC. | $236.12 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $205.66 | 2021-2022 | |
| Daiichi Sankyo INC. | $179.83 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.79 | 2023-2025 | Trulance, Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $125.51 | 2024-2025 | Daxxify |
| Radius Health, INC. | $124.19 | 2019 | |
| Insulet Corporation | $118.09 | 2024 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $94.68 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $72.43 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.59 | 2020-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $69.30 | 2022 | |
| Mylan Specialty L.P. | $51.40 | 2022-2023 | Yupelri |
| Amarin Pharma, INC. | $49.51 | 2020-2021 | |
| Axsome Therapeutics, INC. | $27.19 | 2025 | Symbravo |
| Ultragenyx Pharmaceutical INC. | $26.13 | 2023 | |
| Pfizer INC. | $25.50 | 2023 | |
| Abbott Laboratories | $25.36 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $24.48 | 2019 | |
| Neurocrine Biosciences, INC. | $23.29 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $23.28 | 2024 | Gvoke Hypopen |
| Mayne Pharma Commercial LLC | $17.36 | 2023 | |
| Merck Sharp & Dohme LLC | $16.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Sabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.